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Abstract
Background: In the setting of allogeneic human leukocyte antigen (HLA)-matched bone marrow transplantation,
transplanting male patients with grafts from female donors has been associated with a higher incidence of
graft-versus-host disease (GVHD) and of nonrelapse mortality (NRM). The aim of the current analysis was to
compare transplantation outcomes in male patients given female unrelated cord blood (UCB) versus other
gender combinations.
Patients and methods: Data from 552 consecutive patients with acute myeloid leukemia (AML) given a
single UCB transplantation between 2000 and 2014 were included.
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Results: In comparison with other gender combination, male patients given female UCB (n = 131) had a trend
for a higher incidence of grades II–IV acute GVHD (33 versus 25 %, P = 0.08), a trend for a higher incidence of
NRM (41 versus 33 %, P = 0.06), and a lower leukemia-free (LFS, 30 versus 41 %, P = 0.01) and overall survival
(OS, 33 versus 45 %, P = 0.008). In multivariate analyses, taking into consideration all patients for which data
on HLA-matching and cell dose transplanted were fully available (n = 363), male patients transplanted with a
female UCB had a trend for a higher incidence of grade III–IV acute GVHD (hazard ratio (HR) = 2.0, P = 0.06), a
trend for a higher NRM (HR = 1.5, P = 0.06), and a worse LFS (HR = 1.4, P = 0.04) and OS (HR = 1.3, P = 0.06).
Conclusions: Our data suggest that male patients transplanted with female UCB might have higher risk of
acute GVHD and of NRM leading to worse LFS and OS. These results should be confirmed in other large
cohorts of patients before used for determining the choice of an UCB unit.
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Background
Allogeneic hematopoietic stem cell transplantation from
human leukocyte antigen (HLA)-identical sibling is the
treatment of choice for many patients with acute mye-
loid leukemia (AML) [1, 2]. For patients who lack a
suitable HLA-identical sibling, unrelated cord blood
transplantation (UCBT) and HLA-haploidentical trans-
plantation have emerged as an adequate alternative to
HLA-matched unrelated bone marrow/peripheral blood
stem cell transplantation, particularly for patients at high
risk of rapid disease relapse who urgently need a trans-
plantation [3–7].
Despite major improvements in the field in the last
decades [8], nonrelapse mortality (NRM) has remained
the main cause of failure of UCBT for AML [4]. In the
setting of allogeneic HLA-matched bone marrow or per-
ipheral blood stem cell transplantation, transplanting
male patients with grafts from female donors has been
associated with a higher incidence of graft-versus-host
disease (GVHD) leading to higher NRM and a lower
overall survival (OS) [9, 10]. This is due to recognition by
female donor immune cells of minor histocompatibility
antigens (HA) encoded by genes on the recipient Y
chromosome that are polymorphic to their X chromosome
homologue [11–15]. These HA, termed H-Y antigens, are
highly immunogenic and are expressed throughout the
body [15].
Donor naïve T cells recognizing major or minor histo-
compatibility antigens expressed on normal host tissues
are largely involved in GVHD pathogenesis [16–18].
However, recent findings suggest that effector memory
T cells might also play a role in GVHD pathogenesis in
humans [19].
Despite it has been considered that cord blood T cells
were mostly naïve and dedicated to the development of
tolerance, recent findings evidence the presence of CD4+
T cells with effector memory phenotype and function in
cord blood, representing 1–3 % of CD4+ T cells and
behaving as inflammatory cells with a mixed Th1- and
Th2-like function upon activation [20]. Further, a re-
cent study demonstrated that the presence of HLA-
allele mismatch(es) increased NRM after UCBT [21],
demonstrating that alloreactivity after UCBT was not
restricted to HLA-antigen mismatches between recipi-
ents and UCB but suggesting a role also for minor
HA in GVHD pathogenesis following UCBT. These
findings prompted us to assess whether transplanting
male AML patients with female UCB has an impact
on GVHD and UCBT outcomes.
Results
Patient, disease, and transplant characteristics
Data from 552 consecutive patients with AML given a
single unit UCBT between 2000 and 2014 were included.
Their characteristics are described in Table 1. Briefly,
131 patients were male patients given female UCB, 119
patients were male patients receiving male UCB, and
302 were female patients. In comparison to other pa-
tients, male patients given female UCB were less likely
to have high-risk cytogenetic or secondary leukemia (39
versus 62 %, P = 0.005), were less often transplanted fol-
lowing a reduced-intensity conditioning (24 versus 35 %,
P = 0.03), received more often cyclosporine A alone as
GVHD prophylaxis (39 versus 33 %, P = 0.001), and re-
ceived less total nucleated cells (2.5 versus 2.8 × 107/kg,
P = 0.01). The other characteristics were well-balanced
between the two groups of patients.
Engraftment
Overall, cumulative incidence of neutrophil engraftment
at day 100 was similar in male patients given female
UCB (87 % (95 % confidence interval (CI), 79.5–91.9))
versus in other gender combinations (87.7 % (95 % CI,
84–90.6), P = 0.31). Interestingly, median times for
reaching 0.5 × 109/L neutrophils were 23 days (range, 6–
68 days) in male patients given female UCB versus
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Table 1 Patient, transplant characteristics and GVHD
Other gender combination (n = 421) Female UCB to male recipient (n = 131) Pvaluea
Median patient age, years (range) 43 (18–70) 42 (18–67) 0.48
Median year of SCT, years (range) 2009 (2000–2013) 2009 (2000–2013) 0.24
Recipient M donor F, # (%) 0 (0) 131 (100) /
Recipient M donor M, # (%) 119 (28) 0 (0)
Recipient F donor F, # (%) 157 (37) 0 (0)
Recipient F donor M, # (%) 145 (34) 0 (0)
Median time from diagn to SCT, days 210 231 0.48
Secondary AML, # (%) 72 (17) 18 (14) 0.36
Status at transplantation, # (%)
CR1 233 (55) 59 (45) 0.12
CR2+ 92 (22) 36 (27)
Advanced 96 (23) 36 (27)
Cytogenetics, # (%)
Good riskb 17 (9) 14 (21) 0.005
Intermediate riskc 56 (29) 26 (39)
High riskd 47 (25) 8 (12)
Not reported/failed 229 65
Secondary AML 72 (37) 18 (27)
Recipient CMV-seronegative, # (%) 100 (28) 26 (27) 0.83
Conditioning regimen, # (%)
Myeloablative 271 (65) 94 (76) 0.03
Reduced-intensity 145 (35) 30 (24)
ATG, # (%) 232 (61) 65 (56)
TNC at infusion ×107/kg
Median (range) 2.8 (0.33–40.3) 2.5 (0.4–6.10) 0.01
Missing data (# of patients) 71 19
Number of HLA disparities, # (%)
0–1 mismatch 121 (36) 35 (33)
2–3 mismatches 213 (64) 70 (67) 0.59
Missing data 87 26
Postgrafting immunosuppression, # (%)
CSP alone 140 (33) 51 (39) 0.19
CSP + MMF 215 (51) 55 (42)
Other/missing 66 (16) 25 (19)
Acute GVHD, # (%)
Grades I–IV 171 (43) 59 (49) 0.28
Grades II–IV 99 (25) 40 (33) 0.08
Grades III–IV 43 (11) 18 (15) 0.23
CI chronic GVHD @ 2 years, % 28 21 0.44
Death from GVHD, # (%) 29 (7) 10 (8) 0.77
M male, F female, SCT stem cell transplantation, diagn diagnosis, # number of patients, tacro tacrolimus, CSP cyclosporine A, Mtx methotrexate, MMF
mycophenolate mofetil
aCalculated with χ2 statistics for categorical variables and Mann-Whitney test for continuous variables
bDefined as t(8;21), t(15;17), inv or del (16), acute promyelocyticleukemia, or these abnormalities only or combined with others
cDefined as all cytogenetics not belonging to the good or high risk (including trisomias)
dDefined as 11q23 abnormalities, complex caryotype, and abnormalities of chromosomes 5 and 7
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21 days (range, 3–66 days, P = 0.02) in other gender
combinations (Fig. 1). This could be possibly due to the
fact that male patients given female UCB received less
total nucleated cell counts (TNC), or this could be due
to the fact that, according previous observations, male
CB units include more CD34+ cells and more colony-
forming unit than female ones [22].
Given that cytotoxic T cells (CTLs) directed against
antigens coded by the Y chromosome have been associ-
ated with graft rejection in female patients transplanted
with bone marrows from male HLA-identical siblings
[23], we also compared engraftment kinetics in female
patients transplanted with male UCB (n = 145) versus
other patients (n = 407). Overall, the 100-day cumulative
incidence of neutrophil engraftment was similar in
female patients given male UCB (88.3 % (95 % CI,
81.5–92.7)) and in other gender combinations (87.3 %
(95 % CI, 83.5–90.3), P = 0. 68). Median times for
reaching 0.5 × 109/L neutrophils were 21 days (6–49)
in female patients transplanted with male UCB versus
21 days (3–66 days, P = 0.71) in other patients.
GVHD
Male patients transplanted with female UCB had a trend
for a higher incidence of grades II–IV acute GVHD (33
versus 25 %, P = 0.08) than other patients, while rates of
grades III–IV acute GVHD were 15 versus 11 % (P = 0.2)
in male patients given female UCB and in other patients,
respectively (Table 2). In multivariate analyses, male
patients transplanted with female UCB had significantly
higher incidences of grades II–IV (hazard ratio (HR) 1.7,
95 % CI 1.0–2.7; P = 0.04) and grades III–IV (HR 1.9,
95 % CI 1.0–3.6; P = 0.04) acute GVHD than other
patients. Restricting the multivariate analyses to pa-
tients for which data on TNC transplanted and HLA
compatibility were available (n = 363, including 87
male patients given female UCB), there was still a
trend for a higher incidence of grades II–IV (HR 1.7,
95 % CI 1.0–3.0; P = 0.07) and grades III–IV (HR 2.0,
95 % CI 1.0–3.9; P = 0.06) acute GVHD in male
patients given female UCB, versus other gender com-
binations (Table 3). Restricting the analyses to male
recipients (n = 250), those given female UCB had an
incidence of grades II–IV acute GVHD of 33 %, com-
pared with 27 % (P = 0.32) for those transplanted with
male UCB. Finally, the incidence of grades II–IV
acute GVHD was 21 % in female recipients given
female UCB (P = 0.02 in comparison to male patients
given female UCB).
Interestingly, 2-year incidence of chronic GVHD
tended to be lower in male patients given female UCB in
univariate analysis (16 versus 25 %, P = 0.11) (Table 2),
while in multivariate analysis, the incidence of chronic
GVHD was not different according to gender combin-
ation (HR = 0.8, 95 % CI 0.4–1.4; P = 0.4).
Relapse and NRM
The 2-year incidence of relapse was similar in male
patients given female UCB (29.2 %) and in other patients
(26.2 %, P = 0.4) (Fig. 2). The figures were 22.8 % in male
patients given male UCB (P = 0.35 in comparison to
male patients given female UCB) (Fig. 3) and 26.3 % in
female patients given female UCB (Table 2). In multi-
variate analyses including data from all patients, male
patients given female UCB had a similar incidence of
relapse than other gender combinations (HR = 1.4, 95 %
CI 0.9–2.1; P = 0.13). Similar observations were made
when the analyses were restricted to patients for
whom data on TNC and HLA compatibility were
available (HR = 1.2, 95 % CI 0.8–1.9; P = 0.4) (Table 3).
Factors associated with increased relapse incidence in
multivariate analysis included older recipient age (P = 0.03),
CR2 or advanced disease (P < 0.001) versus CR1, reduced-
intensity conditioning (RIC) (P = 0.04), and secondary AML
(P < 0.001).
Two-year incidences of NRM were 40.8 versus
33.1 % (P = 0.06), respectively, in male patients given
female UCB versus in other gender combinations
(Fig. 2). The figures were 36.6 % in male patients
given male UCB (P = 0.41 in comparison to male
patients given female UCB) (Fig. 3) and 28.4 % in
female patients given female UCB (Table 2). In multi-
variate analyses including data from all patients, male
patients given female UCB had a significantly higher
incidence of NRM than other patients (HR = 1.4, 95 %
Fig. 1 Cumulative incidence of neutrophil engraftment in male
patients given female UCB (n = 131) versus in other gender
combinations (n = 421)
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CI 1.0–2.0; P = 0.04). Restricting the analyses to patients
for which data on TNC and HLA compatibility were avail-
able, there was still a trend for higher NRM in male
patients transplanted with female UCB (HR = 1.5, 95 % CI
1.0–2.2; P = 0.06) (Table 3). Other factors associated with
higher NRM in multivariate analyses included CR2 versus
CR1 (P = 0.01) and the use of anti-thymocyte globulin
(ATG) (P = 0.04).
Overall and leukemia-free survival
Two-year lower leukemia-free survivals (LFS) were 29.9
versus 40.7 % (P = 0.01), respectively, in male patients
given female UCB versus in other patients (Fig. 2). The
figures were 40.7 % in male patients given male UCB (P
= 0.11 in comparison to male patients given female
UCB) (Fig. 3) and 45.3 % in female patients given female
UCB (Table 2). In multivariate analyses including data
from all patients, male patients given female UCB had a
significantly worse LFS than other gender combinations
(HR = 1.4, 95 % CI 1.1–1.8; P = 0.01). Restricting the ana-
lyses to patients for which data on TNC and HLA com-
patibility were available, LFS remained significantly
worse in male patients transplanted with female UCB
(HR = 1.4, 95 % CI 1.0–1.9; P = 0.04) (Table 3). Other
factors associated with worse LFS in multivariate ana-
lysis included older age (P = 0.03), CR2 (P < 0.001) or
advanced disease (P = 0.01) versus CR1, and low number
of TNC infused (P = 0.04).
Two-year OS were 33 versus 45 % (P = 0.008), respect-
ively, in male patients given female UCB versus in other
gender combinations (Fig. 2). The figures were 42.4 % in
male patients given male UCB (P = 0.10) in comparison
to male patients given female UCB) (Fig. 3) and 51 % in
female patients given female UCB (Table 2). In multi-
variate analyses including data from all patients, male
patients given female UCB had a significantly worse OS
than other gender combinations (HR = 1.4, 95 % CI 1.0–
1.8; P = 0.02). Similar qualitative observations were made
when restricting the analyses to patients for which data
on TNC and HLA compatibility were available (HR =
1.3, 95 % CI 1.0–1.8; P = 0.06) (Table 3). Other factors
associated with worse OS in multivariate analysis in-
cluded older age (P = 0.01), CR2 (P < 0.001) or advanced
disease (P = 0.01) versus CR1, and low number of TNC
infused (P = 0.05). Causes of death were comparable in
male patients transplanted with female UCB and in
other gender combination. Specifically, main causes of
death were disease progression (24 % of transplanted
patients), infection (23 % of transplanted patients), and
GVHD (8 % of transplanted patients) in male patients
transplanted with female UCB versus disease progression
(18 % of transplanted patients), infection (17 % of trans-
planted patients), and GVHD (7 % of transplanted
patients) in other gender combinations.
Graft-versus-leukemia effects of chronic GVHD?
Previous studies in the bone marrow or peripheral blood
setting have demonstrated a strong link between chronic
GVHD occurrence and a lower risk of relapse [24–27].
Since we did not observe a lower risk of relapse in male
patients given female UCB, we assessed whether chronic
GVHD was the driver of graft-versus-leukemia effects
after UCBT. We first performed a landmark analysis
selecting patients alive without relapse at 1-year post-
transplant and considering chronic GVHD occurring the
first year post-transplant (n = 179). As shown in the Fig. 4,
2-year cumulative incidence of relapse was 10.8 % (95 %
CI 5.9–17.5 %) in patients without chronic GVHD before
1 year (n = 125), versus 4.5 % (95 % CI 0.8–13.7 %) in pa-
tients with chronic GVHD before 1 year (n = 54) (P = 0.9).
We confirmed the absence of statistically significant asso-
ciation between chronic GVHD and graft-versus-leukemia
effects in a multivariate Cox model that showed that
occurrence of chronic GVHD (assessed as a time-
dependent covariate) was not associated with a lower risk
of relapse (HR = 1.2, 95 % CI 0.7–2.1).
Discussion
Despite cord blood T cells are more tolerant than adult
T cells [28, 29], a recent study demonstrated that the
presence of HLA-allele mismatch(es) increased NRM
after UCBT [21], evidencing that alloreactivity after
UCBT was not restricted to HLA-antigen mismatches
between recipients and UCB and suggesting a possible
role for minor histocompatibility antigens in GVHD
pathogenesis following UCBT. These findings prompted
us to assess whether alloreactivity against H-Y antigens,
a class of well-known highly immunogenic minor HA
which are expressed throughout the body [15], played a
role in the UCBT setting.
Table 2 Two-year outcomes according to gender combination
RI NRM LFS OS cGVHD
Male to male 22.8 % (15.4–31.1) 36.6 % (28.1–45.1) 40.7 % (31.3–50) 42.4 % (32.8–52) 15.7 % (8.3–25.2)
Female to male 29.2 % (21.1–37.8) 40.8 % (32.3–49.2) 29.9 % (21.3–38.6) 33 % (24.1–41.9) 10.1 % (4.7–18)
Male to female 29 % (21–37.5) 35.1 % (26.7–43.6) 35.9 % (27.1–44.7) 40.9 % (32.1–49.8) 13 % (6.9–21.1)
Female to female 26.3 % (18.9–34.2) 28.4 % (20.4–36.9) 45.3 % (36.5–54.1) 51 % (42.3–59.7) 11.6 % (6.1–19)
P 0.8096 0.098598 0.040965 0.030146 0.83169
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Main observations were that male patients given
female UCB had a higher incidence of acute GVHD,
leading to increased NRM and worse LFS and OS. These
observations are in line with what has been observed in
the setting of HLA-identical bone marrow or peripheral
blood stem cell (PBSC) transplantation [9]. This suggests
that even in the presence of HLA-mismatches, donor
cord blood T cells are able to react against H-Y antigens.
However, these results are in contrast to those reported
by Konuma et al. who observed no impact of sex mis-
match on acute GVHD, LFS, nor OS in a cohort of 191
patients who received a single unit UCBT as treatment
for various malignancies [30].
Interestingly, in contrast to what was observed in HLA-
identical bone marrow or PBSC recipients [9, 31, 32], male
recipients of female UCB were not exposed to a higher
incidence of chronic GVHD. The reason for this ap-
parent discrepancy is unclear and might be related to
differences in the biology of cord blood versus bone
marrow transplantation.
Table 3 Multivariate analyses in patients for which data on total
nucleated cell counts (TNC) and HLA compatibility were
available (n = 363, including 87 male patients given female UCB)
(significant factors are in italic)
Logistic regression P OR 95 % CI
AGVH II+ Female to male 0.07 1.7 1.0 3.0
Age (years) 0.60 1.0 1.0 1.0
Status at Tx
CR1 versus CR2 0.07 0.6 0.3 1.0
CR1 versus advanced 0.04 0.5 0.2 1.0
ATG 0.02 0.5 0.3 0.9
RIC 0.20 1.5 0.8 2.9
Sec AML 0.59 0.8 0.4 1.7
Infused cells >2.7 (median) 0.25 0.7 0.5 1.2
Nr mism >1 0.70 1.1 0.7 1.8
AGVH III–IV Female to male 0.06 2.0 1.0 3.9
Age (years) 0.90 1.0 1.0 1.0
Status at Tx
CR1 versus CR2 0.38 0.7 0.3 1.5
CR1 versus advanced 0.05 0.4 0.1 1.0
ATG 0.03 0.5 0.2 0.9
RIC 0.80 1.1 0.5 2.6
Sec AML 0.56 1.3 0.6 3.0
Infused cells >2.7 (median) 0.99 1.0 0.5 1.9
Nr mism >1 0.84 0.9 0.5 1.8
Cox models P HR 95 % CI
NRM Female to male 0.06 1.5 1.0 2.2
Age (years) 0.21 1.0 1.0 1.0
Status at Tx
CR1 versus CR2 0.01 0.5 0.3 0.8
CR1 versus advanced 0.62 0.9 0.5 1.5
ATG 0.04 1.5 1.0 2.4
RIC 0.09 0.6 0.4 1.1
Sec AML 0.06 1.6 1.0 2.4
Infused cells >2.7 (median) 0.18 0.8 0.5 1.1
Nr mism >1 0.18 0.8 0.5 1.1
RI Female to male 0.40 1.2 0.8 1.9
Age (years) 0.03 1.0 1.0 1.0
Status at Tx
CR1 versus CR2 <10–4 0.2 0.1 0.4
CR1 versus advanced <10–4 0.3 0.2 0.5
ATG 0.88 1.0 0.6 1.5
RIC 0.04 1.7 1.0 2.9
sec AML 0.00 0.2 0.1 0.4
Infused cells > 2.7 (median) 0.06 0.7 0.5 1.0
Nr mism > 1 0.64 0.9 0.6 1.4
Table 3 Multivariate analyses in patients for which data on total
nucleated cell counts (TNC) and HLA compatibility were
available (n = 363, including 87 male patients given female UCB)
(significant factors are in italic) (Continued)
LFS Female to male 0.04 1.4 1.0 1.9
Age (years) 0.03 1.0 1.0 1.0
Status at Tx
CR1 versus CR2 <10–4 0.4 0.3 0.5
CR1 versus advanced 0.01 0.6 0.4 0.9
ATG 0.14 1.3 0.9 1.7
RIC 0.90 1.0 0.7 1.5
Sec AML 0.17 0.8 0.5 1.1
Infused cells >2.7 (median) 0.04 0.7 0.6 1.0
Nr mism >1 0.23 0.8 0.6 1.1
OS Female to male 0.06 1.3 1.0 1.8
Age (years) 0.01 1.0 1.0 1.0
Status at Tx
CR1 versus CR2 <10–4 0.4 0.3 0.5
CR1 versus advanced 0.01 0.6 0.4 0.9
ATG 0.23 1.2 0.9 1.7
RIC 0.35 0.8 0.6 1.2
Sec AML 0.35 0.8 0.6 1.2
Infused cells >2.7 (median) 0.05 0.8 0.6 1.0
Nr mism >1 0.40 0.9 0.7 1.2
HR hazard ratio, CI confidence interval, P P value, AGVHD II+ grades II–IV acute
GVHD, AGVHD III–IV grades III–IV acute GVHD, cGVHD cumulative incidence of
chronic graft-versus-host disease, NRM cumulative incidence of nonrelapse
mortality, RI cumulative incidence of relapse, LFS leukemia-free survival, OS
overall survival, Tx transplantation, CR complete remission, advanced not
in complete remission, ATG anti-thymocyte globulin, RIC reduced-intensity
conditioning, sec AML secondary acute myeloid leukemia
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Despite having a higher incidence of acute GVHD, male re-
cipients of female UCB were not protected from relapse.
While occurrence of acute and/or chronic GVHD has been
associated with a lower risk of relapse in AML patients in the
setting of HLA-matched bone marrow or peripheral blood
stem cells transplantation [26, 33, 34], the impact of GVHD
on transplantation outcomes in the UCBT setting remains
to be investigated. Our current data suggest that transplant-
ing male patients with female UCB is not associated with
increased graft-versus-leukemia effects, in contrast to what
has been observed after HLA-identical bone marrow trans-
plantation [9]. These results mirror those observed in a
study assessing the impact of HLA-allele mismatches in the
UCBT setting where increasing mismatching correlated
with acute GVHD and nonrelapse mortality but not with a
protection from relapse [21]. These results are also in line
with those reported by Konuma et al. who observed no im-
pact of sex mismatch on relapse incidence after single unit
UCBT [30].
The current study also confirmed a detrimental im-
pact of ATG on NRM as recently reported in a study
including data from patents given UCB after myeloa-
blative conditioning [35], probably due to the negative
impact of ATG on immune recovery after allogeneic
stem cell transplantation [36]. However, ATG had no
impact on relapse incidence, in agreement with recent
observations in the peripheral blood stem cell setting
[37–39]. Further, as previously observed in the UCB
Fig. 2 Relapse incidence (a), NRM (b), LFS (c), and overall survival (d) in male patients given female URD (n = 131) versus other gender
combinations (n = 421)
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setting [4, 40], older age was associated with worse
LFS and OS. Interestingly, while patients given RIC
had a higher incidence of relapse, this did not trans-
late to worse LFS or OS due to a trend to lower
NRM in patients given RIC (P = 0.09), as previously
observed in the setting of UCBT as treatment for
ALL [40]. In addition, confirming previous observa-
tions, low TNC infused correlated to worse OS [29].
Finally, as expected, advanced disease status at trans-
plantation had a negative impact of on all transplant-
ation outcomes, while patients with secondary (versus
primary) AML had a higher risk of relapse in contrast
to recent observations in the PBSC transplantation
setting [41].
There are some limitation in our study including its
design (retrospective registry survey) and the surpris-
ing relative imbalance between the two groups. We
tried to address these issues by performing multivari-
ate analyses. Nevertheless, current results should be
taken with some caution and should be confirmed in
other large cohort of patients before recommenda-
tions can be made regarding the choice of the gender
of the UCB in male patients with AML. Further,
translational research looking at the presence (or
Fig. 3 Relapse incidence (a), NRM (b), LFS (c), and overall survival (d) in male patients given female URD (n = 131) versus in male patients given
male UCB (n = 119)
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absence) of CTLs [23] or antibodies [14] directed
against antigens coded by the Y chromosome in male
patients transplanted with female UCT are needed.
Conclusions
In summary, our data suggest that male AML patients
transplanted with female UCB might have higher risk of
acute GVHD and of NRM leading to worse LFS and OS.
These results should be confirmed in other large cohorts
of patients before used for determining the choice of an
UCB unit.
Patients and methods
Data Collection
This survey is a retrospective study performed by the
Acute Leukemia Working Party (ALWP) of the European
Group for Blood and Marrow Transplantation (EBMT)
group and by Eurocord. EBMT registry is a voluntary
working group of more than 500 transplant centers, par-
ticipants of which are required once a year to report all
consecutive stem cell transplantations and follow-up.
Eurocord collects data on UCBT performed in >50 coun-
tries worldwide and >500 transplant centers, mainly
EBMTcenters. Population selection criteria included adult
recipients, primary or secondary AML, first allogeneic
stem cell transplantation, and single-unit UCBT per-
formed from 2000 to 2014. Grading of acute and chronic
GVHD was performed using established criteria [42].
HLA compatibility was based on low-resolution typing for
HLA-A and HLA-B and high-resolution typing for HLA-
DRB1. For the purpose of this study, all necessary data
were prospectively collected according to EBMT and
Eurocord guidelines.
Ethics
The scientific boards of the ALWP of EBMT and of
Eurocord approved this study.
Statistical analyses
Data from all patients meeting the inclusion/exclusion
criteria were included in the analyses(additional file).
Start time was date of transplant for all endpoints.
Neutrophil engraftment was defined as first of three
consecutive days with a neutrophil count of at least
0.5 × 109/L, while platelet engraftment was defined as
the first of seven consecutive days of an unsupported
platelet count of at least 20 × 109/L.
To evaluate the relapse incidence, patients dying either
from direct toxicity of the procedure or from any other
cause not related to leukemia were censored. NRM was
defined as death while in CR. Patients were censored at
the time of relapse or of the last follow-up. Cumulative
incidence functions (CIF) were used for relapse inci-
dence and NRM in a competing risk setting, since death
and relapse were competing together.
For estimating the cumulative incidence of chronic
GVHD, death was considered as a competing event. OS
and leukemia-free survival (LFS) were estimated using
the Kaplan-Meier estimates. Univariate analyses were
done using Gray’s test for CIF and log rank test for OS
and LFS. Multivariate analyses adjusted for differences
between groups were performed using Cox proportional
hazards regression models for OS, LFS, relapse inci-
dence, and NRM and using multivariate logistic regres-
sion for acute GVHD. The impact of chronic GVHD on
the risk of relapse was assessed by performing a land-
mark analysis 1 year after transplantation and in a multi-
variate time-dependent Cox model in which chronic
GVHD was modeled as a time-dependent covariate. All
tests were two sided. The type I error rate was fixed at
0.05 for determination of factors associated with time to
event outcomes. Statistical analyses were performed with
SPSS 19 (SPSS Inc, Chicago, IL) and R 2.13.2 (R Devel-
opment Core Team, Vienna, Austria) software packages.
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Additional file 1: List of institutions reporting data in this study.
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